💊 Medicamentos A-Z 🧬 Alvos 🛠 Ferramentas 📚 Guias
Todos os Medicamentos Classes de Medicamentos Áreas Terapêuticas Efeitos Colaterais
Guias Glossário Linha do Tempo
Comparações Percursos de Medicamentos Famílias de Medicamentos
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Acarbose

CHEMBL404271 Phase 4 Aprovado Oligosaccharide
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
645.6 g/mol
LogP
-8.8
Phase
4

An oral medication that slows the digestion of carbohydrates in the intestine by blocking enzymes that break down complex sugars, resulting in a more gradual rise in blood glucose after meals. It is used alongside diet and exercise to manage type 2 diabetes and lowers after-meal blood sugar spikes without causing low blood sugar on its own. Digestive side effects such as gas and bloating are common, especially early in treatment, and tend to improve over time.

Peso Molecular

645,6000 g/mol

LogP

-8,80

TPSA

329,00 Ų

Regra dos 5 de Lipinski

Reprovado

Áreas Terapêuticas

Cardiovascular Disease Non-Alcoholic Fatty Liver Disease Stroke Obesity Type 2 Diabetes Hypertension Hepatitis C

Mecanismo de Ação

Selectively blocks angiotensin II type 1 (AT1) receptors, preventing the vasoconstrictive and aldosterone-secreting effects of angiotensin II. This results in vasodilation, reduced sodium retention, and decreased blood pressure.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mecanismo

Selectively blocks angiotensin II type 1 (AT1) receptors, preventing the vasoconstrictive and aldosterone-secreting effects of angiotensin II. This results in vasodilation, reduced sodium retention, and decreased blood pressure.

Estrutura 2D

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
C[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O[C@H]3[C@H](O)[C@@H](O)C(O)O[C@@H]3CO)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O

                

                

                
                

                    
InChI

                    
InChI=1S/C25H43NO18/c1-6-11(26-8-2-7(3-27)12(30)15(33)13(8)31)14(32)19(37)24(40-6)43-22-10(5-29)42-25(20(38)17(22)35)44-21-9(4-28)41-23(39)18(36)16(21)34/h2,6,8-39H,3-5H2,1H3/t6-,8+,9-,10-,11-,12-,13+,14+,15+,16-,17-,18-,19-,20-,21-,22-,23?,24-,25-/m1/s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C25H43NO18

                    

                    
                    

                        
HBD / HBA

                        
14 / 19

                    

                    
                    

                        
Ligações Rotacionáveis

                        
13

                    

                    
                    
                    

                        
Átomos Pesados

                        
44

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Perguntas frequentes

                

                    
                    

                        
                        

                            
An oral medication that slows the digestion of carbohydrates in the intestine by blocking enzymes that break down complex sugars, resulting in a more gradual rise in blood glucose after meals. It is used alongside diet and exercise to manage type 2 diabetes and lowers after-meal blood sugar spikes without causing low blood sugar on its own. Digestive side effects such as gas and bloating are common, especially early in treatment, and tend to improve over time.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Selectively blocks angiotensin II type 1 (AT1) receptors, preventing the vasoconstrictive and aldosterone-secreting effects of angiotensin II. This results in vasodilation, reduced sodium retention, and decreased blood pressure.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Acarbose is an approved drug. It has reached clinical phase 4. It is classified as a Oligosaccharide.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL404271.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 9811704.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
Aviso Médico

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.